CliffBio
small molecule

VIRAMUNE XR

NEVIRAPINE

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand nameVIRAMUNE XR
Active ingredientNEVIRAPINE
Strength400MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
8460704March 2029use U-1409

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIRAMUNE XR patent cliff — loss of exclusivity March 2029 | CliffBio